AR089232A1 - Potenciacion inducida por inhibidores de pde4 en el tratamiento de la leucemia - Google Patents

Potenciacion inducida por inhibidores de pde4 en el tratamiento de la leucemia

Info

Publication number
AR089232A1
AR089232A1 ARP120104706A ARP120104706A AR089232A1 AR 089232 A1 AR089232 A1 AR 089232A1 AR P120104706 A ARP120104706 A AR P120104706A AR P120104706 A ARP120104706 A AR P120104706A AR 089232 A1 AR089232 A1 AR 089232A1
Authority
AR
Argentina
Prior art keywords
branched
linear
optionally substituted
halogen atoms
combination according
Prior art date
Application number
ARP120104706A
Other languages
English (en)
Inventor
Lunghi Paolo
Bonati Antonio
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Publication of AR089232A1 publication Critical patent/AR089232A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Reivindicación 1: Una combinación caracterizada porque comprende: i) un compuesto de fórmula general (1) en donde: n es 0 ó 1; R¹ y R² pueden ser iguales o diferentes, y se eligen a partir del grupo que consiste en: alquilo C₁₋₆ lineal o ramificado, opcionalmente sustituido con uno o más átomos de halógeno; OR³ en donde R³ es un alquilo C₁₋₆ lineal o ramificado opcionalmente sustituido con uno o más átomos de halógeno o grupos cicloalquilo C₃₋₇; y HNSO₂R⁴ en donde R⁴ es un alquilo C₁₋₄ lineal o ramificado opcionalmente sustituido con uno o más átomos de halógeno, en donde al menos uno de R¹ y R² es HNSO₂R⁴; ii) un retinoide y/o iii) un derivado de arsénico, que se administra en forma simultánea, secuencial o separada. Reivindicación 3: La combinación de acuerdo a la reivindicación 2, caracterizada porque el compuesto de fórmula general (1) es éster 1-(3-ciclopropilmetoxi-4-difluorometoxi-fenil)-2-(3,5-dicloro-1-oxi-piridin-4-il)-etílico de ácido (-)-3-ciclopropilmetoxi-4-metanosulfonilamino-benzoico (C2). Reivindicación 5: La combinación de acuerdo a la reivindicación 4, caracterizada porque el derivado de arsénico es trióxido de arsénico (ATO). Reivindicación 8: La combinación de acuerdo a la reivindicación 7, caracterizada porque el retinoide es ácido aII-trans retinoico (ATRA).
ARP120104706A 2011-12-16 2012-12-13 Potenciacion inducida por inhibidores de pde4 en el tratamiento de la leucemia AR089232A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11194076 2011-12-16

Publications (1)

Publication Number Publication Date
AR089232A1 true AR089232A1 (es) 2014-08-06

Family

ID=47563345

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120104706A AR089232A1 (es) 2011-12-16 2012-12-13 Potenciacion inducida por inhibidores de pde4 en el tratamiento de la leucemia

Country Status (3)

Country Link
US (1) US20130156865A1 (es)
AR (1) AR089232A1 (es)
WO (1) WO2013087749A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3293176T3 (pl) * 2013-10-22 2021-06-28 Chiesi Farmaceutici S.P.A. Sposób wytwarzania inhibitora PDE4
WO2015068142A2 (en) * 2013-11-11 2015-05-14 Cellworks Group, Inc. Compositions, process of preparation of said compositions, uses and method of management of myeloproliferative disorder
CN104730200A (zh) * 2013-12-20 2015-06-24 辰欣药业股份有限公司 一种用电位滴定法测定罗氟司特含量的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004204355B2 (en) * 2003-01-14 2009-12-17 Nycomed Gmbh PDE4 inhibitors for the treatment of neoplasms of lymphoid cells
WO2009147169A1 (en) * 2008-06-03 2009-12-10 Universite Paris Diderot-Paris 7 Pharmaceuticl compositions useful for the treatment of cancers, in particular acute myeloid leukemia and acute promyelocytic leukemia
EP2216327A1 (en) * 2009-02-06 2010-08-11 CHIESI FARMACEUTICI S.p.A. Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors

Also Published As

Publication number Publication date
WO2013087749A1 (en) 2013-06-20
US20130156865A1 (en) 2013-06-20

Similar Documents

Publication Publication Date Title
BR112015028870A2 (pt) estruturas fibrosas hidroentrelaçadas
TR201900050T4 (tr) Kaynaştırılmış heterosiklik bileşik ve bunun haşere kontrol uygulaması.
UY34763A (es) Inhibidores de la agregación plaquetaria
CU20140105A7 (es) Composición para el control de plagas que incluye un derivado de iminopiridina novedoso
UY34393A (es) Compuestos de tetrahidroisoquinolina sustituidos como inhibidores del factor xia
CO7350620A2 (es) Nuevos derivados de piridina
UY34550A (es) Bencilpirazoles sustituidos
CR20140468A (es) Inhibidores de diacilglicerol aciltransferasa 2
CR20140231A (es) Derivados de ácido benzotiazol-6-il acético y su uso para tratar una infección por vih
UY34057A (es) Inhibidores del virus de la hepatitis c
UY34203A (es) Compuestos fungicidas 242-halogenalquil-4- (fenoxi)-fenil1-141,2,4ttriazol-1-il-etanol sustituidos
UY34365A (es) Compuestos heterociclicos
JP2011256183A5 (es)
AR094959A1 (es) Compuestos de imidazo piridina
AR098274A1 (es) Inhibidor de grelina o-acil transferasa
UY33936A (es) Derivados de fluoro-piridinona útiles como agentesantibacterianos.
CR20130539A (es) Triazolopiridinas
UY34490A (es) Composición herbicida que contiene ciertos ácidos de piridina carboxílicos y el ácido (2,4-diclorofenoxi) acético
BR112019001980A2 (pt) inibidor de ido1 e método de preparação e aplicação do mesmo
EA201391303A1 (ru) Амиды n-(1,2,5-оксадиазол-3-ил)-, n-(тетразол-5-ил)- и n-(триазол-5-ил)бициклоарилкарбоновых кислот и их применение в качестве гербицидов
UY33930A (es) Inhibidores novedosos de quinasas
ECSP13012366A (es) Procedimiento de preparación de la sal de l-arginina de perindoprilo
AR089232A1 (es) Potenciacion inducida por inhibidores de pde4 en el tratamiento de la leucemia
CR20140114A (es) Compuestos de benzotiazolona
AR088358A1 (es) Proceso de obtencion de acidos isoxazolil-metoxi-nicotinicos

Legal Events

Date Code Title Description
FB Suspension of granting procedure